Alzheimer's DMT Market to Grow at 67.8% CAGR Through 2030
BOSTON, Aug. 13, 2025 /PRNewswire/ -- According to the latest study from BCC Research, the "Disease-Modifying Therapies for Alzheimer's Disease: Global Markets" is projected to reach $13.1 billion by the end of 2030, growing at a CAGR of 67.8% during the forecast period of 2025-2030.
The Alzheimer's disease (AD) disease-modifying therapies (DMTs) market is in its early stages, with lecanemab being the first fully approved DMT by the U.S. FDA in July 2023. Several other DMTs in late-stage trials could significantly expand the market if approved. BCC Research forecasts future revenues based on current products and potential candidates. The report analyzes the market by target type (anti-amyloid and emerging targets), drug (Leqembi, Kisunla, and others), molecule type (large and small), and region (Asia-Pacific, North America, Europe, South America, and the Middle East and Africa).
This report is particularly relevant today because the Alzheimer's disease (AD) DMT market is in its early stage of development, with several therapies currently in late-stage clinical trials. If these therapies are approved, they could significantly expand the market and reshape treatment options. In this context, studying the AD DMTs market is both timely and crucial for pharmaceutical companies and industry stakeholders. The report offers essential market and business insights, helping participants in the AD drugs industry make informed decisions and prepare for upcoming opportunities.
The factors driving the market's growth include:
High Unmet Need in AD Treatment: Alzheimer's disease currently lacks effective long-term treatments, with existing options only offering temporary symptom relief. This creates a strong demand for therapies that can slow or halt disease progression, encouraging investment, innovation, and regulatory support for disease-modifying therapies.
Use of Biomarkers to Accelerate Approvals of AD DMTs: Biomarkers like amyloid-beta and tau proteins help detect Alzheimer's early and track its progression. Their use in clinical trials allows faster and more precise evaluation of new therapies, enabling quicker regulatory approvals and more targeted treatment development.
Request a sample copy of the global and regional markets for disease-modifying therapies for Alzheimer's disease report.
Report Synopsis
Report Metric
Details
Base year considered
2024
Forecast period considered
2025-2030
Base year market size
$235.8 million
Market size forecast
$13.1 billion
Growth rate
CAGR of 67.8% for the forecast period of 2025-2030
Segments covered
Target Type, Drug Type, Drug Molecule Type, and Region
Regions covered
North America, Europe, Asia-Pacific, South America, Middle East and Africa
Market drivers
• High unmet need in AD treatment.
• Use of biomarkers to accelerate AD DMTs approval.
Interesting facts:
As of May 2025, over half of the AD therapeutic candidates in phase 3 trials are disease modifying small molecules (Clinicaltrials.gov).
There are very few DMTs targeting the moderate to advanced stages of AD.
Emerging startups:
AgeneBio Inc.: The company is investigating AGB101 (levetiracetam) in phase 2 and 3 clinical trials for the treatment of hippocampal overactivity and to assess its ability to control progression to Alzheimer's dementia. Currently, no treatments have shown these benefits.
TauRx Pharmaceuticals: TauRx's research centers on tau aggregation inhibitors (TAIs), which aim to prevent or reverse the formation of tau protein tangles in the brain. TRx0237 is a late-stage AD therapeutic candidate. It is an oral tau aggregation inhibitor designed for early intervention to modify the underlying disease process and slow the progression of AD.
The report addresses the following questions:
What are the projected size and growth rate of the Alzheimer's disease-modifying therapies market?- The global Alzheimer's DMT market was estimated at $235.8 million in 2024. The market is projected to reach $13.1 billion in by the end of 2030, growing at a CAGR of 67.8% during the forecast period.
Which market segments are covered in the report?- Target type, drug, molecule type, and region.
Which target type will be dominant through 2030?- By target type, the anti-amyloid segment is expected to be the largest market by the end of 2030.
Which molecule type market is growing the fastest?- The large molecule segment is the fastest growing market.
What are the key challenges in of the market?- Modest clinical benefits, significant risk of side effects, and the high cost of approved DMTs remain challenges to the widespread adoption of these drugs.
Market leaders include:
ALZHEON INC.
ANAVEX LIFE SCIENCES CORP.
ANNOVIS BIO INC.
BIOGEN
BIOVIE INC.
EISAI CO. LTD.
JOHNSON & JOHNSON
LILLY
NOVO NORDISK A/S
TAURX PHARMACEUTICALS LTD.
Related reports:
Neurology Market: A BCC Research Overview: This report offers a detailed analysis of the global neurology therapeutics market, segmented by conditions such as Parkinson's, Alzheimer's, epilepsy, autism, psychotic disorders, multiple sclerosis, and brain tumors. It explores drug classes, market dynamics, pipeline developments, competitive landscape, and regional trends across North America, Europe, Asia-Pacific, and the Rest of the World, providing insights into current and future market potential.
Alzheimer's Disease Therapeutics and Diagnostics: Global Markets: This report provides an overview of the global Alzheimer's disease diagnostics and therapeutics market, focusing exclusively on biomarker tests for diagnostics and approved pharmacological treatments for therapeutics. It excludes cognitive tests, neuroimaging, procedural interventions, and off-label drug use. The market is segmented by test type, drug class, disease stage, and region, and includes analysis of clinical trials, innovations, and emerging trends.
Purchase a copy of the report direct from BCC Research.
For further information on any of these reports or to make a purchase, contact info@bccresearch.com.
About BCC Research
BCC Research market research reports provide objective, unbiased measurement and assessment of market opportunities. Our experienced industry analysts' goal is to help you make informed business decisions free of noise and hype.
Contact Us
Corporate HQ: 50 Milk St., Ste. 16, Boston, MA 02109, USA
Email: info@bccresearch.com
Phone: +1 781-489-7301
For media inquiries, email press@bccresearch.com or visit our media page for access to our market research library.
Any data and analysis extracted from this press release must be accompanied by a statement identifying BCC Research LLC as the source and publisher.
Logo - https://mma.prnewswire.com/media/2183242/5458209/BCC_Research_Logo.jpg
View original content to download multimedia:https://www.prnewswire.com/news-releases/alzheimers-dmt-market-to-grow-at-67-8-cagr-through-2030--302528768.html
SOURCE BCC Research LLC
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Newsweek
25 minutes ago
- Newsweek
Salad Recall Sparks Highest Risk Warning For Consumers
Based on facts, either observed and verified firsthand by the reporter, or reported and verified from knowledgeable sources. Newsweek AI is in beta. Translations may contain inaccuracies—please refer to the original content. Recalls of 15 products containing tuna salad have been given the highest-alert warning by the U.S. Food and Drug Administration (FDA). The recalls relate to possible contamination with listeria monocytogenes in breadcrumbs used as an ingredient by Idaho-based company Reser's Fine Food. Albertsons, Randalls and Tom Thumb stores in Arkansas, Louisiana, Oklahoma and Texas, and Jewel Osco stores in Illinois, Indiana and Iowa issued the recalls in mid-July. The FDA classified the recalls as Class I, the highest of three levels, on August 13. Why It Matters "Listeria monocytogenes is an organism which can cause serious and sometimes fatal infections in young children, frail or elderly people and others with weakened immune systems," the FDA warned in an initial recall notice. "Although healthy individuals may suffer only short-term symptoms such as high fever, severe headache, stiffness, nausea, abdominal pain and diarrhea, Listeria infection can cause miscarriages and stillbirths among pregnant women." Stock image of a tuna salad. Stock image of a tuna salad. Getty Images What To Know Consumers who purchased these products should not eat them and are advised to either discard the items or return them to their local store for a full refund. In such cases, the FDA urges anyone who bought or received recalled products to thoroughly clean and sanitize any surfaces, utensils, or containers that may have come into contact with them, in order to reduce the risk of cross-contamination The recall products to be classified Class I are as follows: Product Description Code Information READY MEALS QUAD TUNA SALAD Jul 17 25; Jul 18 25; Jul 19 25; UPC: 21500300000 READY MEALS QUAD TUNA SALAD Jul 17 25; Jul 18 25; Jul 19 25; UPC: 21500300000 READY MEALS TUNA SALAD Jul 17 25; Jul 18 25; Jul 19 25; UPC: 29486900000 READY MEALS SUSTAINABLE TUNA SALAD CROISSANT SANDWICH Jul 17 25; Jul 18 25; Jul 19 25; UPC: 21372500000 Jewel Osco TUNA SALAD Jul 17 25; Jul 18 25; Jul 19 25; UPC: 21680700000 READY MEALS PREMIUM TUNA SALAD Jul 17 25; Jul 18 25; Jul 19 25; Jul 24 25; Jul 25 25; Jul 26 25; Jul 27 25; Jul 28 25; Jul 29 25; UPC: 21425000000 READY MEALS TUNA SALAD SNACKER TRAY Jul 17 25; Jul 18 25; Jul 19 25; Jul 24 25; Jul 25 25; Jul 26 25; Jul 27 25; Jul 28 25; Jul 29 25; UPC: 21151300000 READY MEALS TUNA SALAD CROISSANT SANDWICH Jul 16 25; Jul 17 25; Jul 18 25; Jul 23 25; Jul 24 25; Jul 25 25; Jul 26 25; Jul 27 25; Jul 28 25; UPC: 21788400000 READY MEALS TUNA SALAD OVER BED OF LETTUCE Jul 16 25; Jul 17 25; Jul 18 25; Jul 23 25; Jul 24 25; Jul 25 25; Jul 26 25; Jul 27 25; Jul 28 25; UPC: 21786400000 Randalls PREMIUM TUNA SALAD Jul 17 25; Jul 18 25; Jul 19 25; Jul 24 25; Jul 25 25; Jul 26 25; Jul 27 25; Jul 28 25; Jul 29 25; UPC: 21228800000 Randalls MINI SALAD CROISSANT 16 INCH TRAY Jul 16 25; Jul 17 25; Jul 18 25; Jul 23 25; Jul 24 25; Jul 25 25; Jul 26 25; Jul 27 25; Jul 28 25; UPC: 27841300000 Randalls MINI SALAD CROISSANT 18 INCH TRAY Jul 16 25; Jul 17 25; Jul 18 25; Jul 23 25; Jul 24 25; Jul 25 25; Jul 26 25; Jul 27 25; Jul 28 25; UPC: 27841200000 Randalls SALAD SANDWICH 12 INCH TRAY Jul 16 25; Jul 17 25; Jul 18 25; Jul 23 25; Jul 24 25; Jul 25 25; Jul 26 25; Jul 27 25; Jul 28 25; UPC: 27841500000 Randalls SALAD SANDWICH 16 INCH TRAY Jul 16 25; Jul 17 25; Jul 18 25; Jul 23 25; Jul 24 25; Jul 25 25; Jul 26 25; Jul 27 25; Jul 28 25; UPC: 27841400000 Jewel Osco CLUB SANDWICHES WITH SALAD Jul 16 25; Jul 17 25; Jul 18 25; UPC: 29125900000 "Listeria monocytogenes can survive in refrigerated temperatures and can easily spread to other foods and surfaces," the FDA warned in recall notices. No adverse reactions connected with these products had been reported when the initial recalls were issued. Anyone concerned about an injury or illness should contact a healthcare provider, the FDA added. Consumers can contact Albertsons Companies' Customer Service Center at 1-877-723-3929 Monday through Friday from 5 a.m. to 9 p.m. PST. What Happens Next The recalls remain active.
Politico
an hour ago
- Politico
How thyroid drugs became a MAHA flashpoint
Driving the Day THYROID DRUG PUSHBACK — A recent FDA letter to makers and distributors of a decades-old thyroid medication has stoked outrage among a subset of pharmacists and wellness influencers linked to the Make America Healthy Again movement led by Health Secretary Robert F. Kennedy Jr. The products in question are known as desiccated thyroid extracts, which are 'the dried, ground-up thyroid glands of pigs,' according to Tenille Davis, the Alliance for Pharmacy Compounding's chief advocacy officer. The animal-derived drugs, which predate the FDA as an institution, are among the treatment options for people with an underactive thyroid, or hypothyroidism, though the agency says most patients take FDA-approved synthetic hormone replacements. But last week, the FDA informed firms that market animal-derived versions that it would take action if they continued to sell them. The agency said it received more than 500 adverse event reports from the products between 1968 and February 2025 — with a substantial increase seen between 2019 and 2020. 'FDA is committed to pursuing the first-ever approval of desiccated thyroid extract, pending results of the ongoing clinical trials. In the mean time, we will ensure access for all Americans,' FDA Commissioner Marty Makary posted on social media platform X on Thursday. The agency said it would give 'adequate time' for providers to transition patients to FDA-approved options, noting it expects them to need about 12 months. The uproar: Some wellness influencers with ties to Kennedy panned the FDA's move on social media and urged their followers to sign online petitions urging the agency to back down. Brigham Buhler, who owns the compounding pharmacy ReviveRX and is aligned with many of Kennedy's policy priorities, suggested the agency's position favors AbbVie, which makes synthetic thyroid medicines and has another candidate in clinical trials. 'Is this an example of fda working for Pharma again to create another monopoly over a drug that has been used for 100 plus years so that they can raise the prices like Pharma bro Martin [Shkreli] again?' he said in a text message. AbbVie said it would work with the agency to ensure access is not interrupted. The FDA did not respond to an interview request. 'With our ongoing clinical trials, we remain committed to these patients and their providers,' AbbVie posted Thursday on X. Why it matters: The drugs are used to prevent side effects of hypothyroidism, such as fatigue and weight gain. A doctor must closely monitor dosing because the margin between a low dose that might not be effective and a high dose that could cause side effects is small. Davis said some patients don't respond well to the synthetic drugs. While their blood panels might suggest the medication works, she said, patients continue to 'feel really crappy' until they switch to the animal-derived versions. Those people might be in the minority, Davis said, but they're still a sizeable population given the number of Americans with hypothyroidism. 'It's happened enough times where these patients aren't crazy,' she said. IT'S FRIDAY. WELCOME BACK TO PRESCRIPTION PULSE. The FDA cautioned against sunscreens that come in mousse form this week, saying they might not be effective. Send tips to David Lim (dlim@ @davidalim or davidalim.49 on Signal) and Lauren Gardner (lgardner@ @Gardner_LM or gardnerlm.01 on Signal). AROUND THE AGENCIES VAX SAFETY GROUP IS BACK — HHS said Thursday it's bringing back a 1990s-era task force on safer childhood vaccines, fulfilling a demand made by the secretary's old colleagues at an anti-vaccine group, Lauren reports. The department is reinstating the group, which was created by the 1986 law establishing a compensation program for vaccine-injured people, 'to improve the safety, quality, and oversight of vaccines administered to American children,' HHS said in a statement. NIH Director Jay Bhattacharya will lead the effort, with leaders from the FDA and the CDC participating. An HHS spokesperson didn't specify who else from the agencies would sit on the panel. HHS Secretary Robert F. Kennedy Jr. has long questioned the safety of the modern childhood vaccination schedule, suggesting the number of shots young kids receive may contribute to myriad chronic conditions, including autism. Dozens of scientific studies have found no link between vaccines and autism. Background: The Task Force on Safer Childhood Vaccines' earlier iteration disbanded in 1998 after issuing recommendations for ways the government could support the development of safer vaccines, improve adverse event surveillance and educate the public about their benefits and risks. But the law that established the task force also directed HHS to report to Congress every two years about actions it had taken to promote safer products — a paperwork burden that the Kennedy-founded group Children's Health Defense says was never met. HHS's announcement came the day before the federal government is due to respond to CHD's May lawsuit regarding Kennedy's failure to reestablish the task force. In a deadline extension request filed last month and approved, Justice Department lawyers indicated the parties could reach a settlement. 'It took nearly 30 years for HHS to do this, but at last, we have an HHS secretary who is following the law on this vital issue,' CHD President and CEO Mary Holland said in a statement. What's next: The task force is supposed to collaborate with the Advisory Commission on Childhood Vaccines, a lesser-known federal advisory committee in the vaccine space, in developing its recommendations. The secretary can appoint up to nine ACCV voting members, evenly split among health professionals, attorneys and the general public — at least two of whom have children who were injured by a vaccine. Of the current roster, no member's term ends before July 2026, and it's unclear whether Kennedy might try to shake it up before then as he did with the CDC's independent vaccine panel. Drug Pricing LILLY'S MFN PLAY? Indianapolis-based Eli Lilly said Thursday it would raise prices on its drugs in European markets as a way to lower costs for American consumers — an apparent response to President Donald Trump's most-favored-nation pressure campaign, Lauren writes. The statement came two weeks after Trump sent letters to the leaders of major drug manufacturers — and posted them on social media — demanding they embrace most-favored-nation pricing that ties U.S. prices to lower figures paid in other wealthy nations or face unknown consequences. 'Lilly supports the administration's goal of keeping the United States the world's leading destination for biopharmaceutical research and manufacturing, and the objective of more fairly sharing the costs of breakthrough medical research across developed countries,' the company said in a statement. When asked to elaborate on how the drugmaker will achieve that goal — and which drugs may be implicated — a company spokesperson referred to the online statement. Eye on the FDA GOLD STANDARD SCIENCE? The FDA quietly posted a new staff manual laying out the 'core tenets of gold standard science' online this week, following up on an executive order from President Donald Trump in May. 'In conducting our mission to protect and promote public health, FDA must generate and evaluate science in a manner that ensures FDA will make sound, objective decisions,' the staff manual states. 'Preserving and promoting GSS is essential to ensuring that FDA's mission succeeds and our regulatory decisions advance public health.' The document says the FDA will focus on reproducibility and replicable science, transparency in its research process, communication of errors and uncertainty and encouragement of collaborative and interdisciplinary approaches in science. It also says the FDA will embrace 'a culture of constructive skepticism in science through policies and programs that emphasize critical evaluation, transparency and objectivity,' values science that includes testable hypotheses with 'explicitly defined measurable criteria for falsification,' and recognizes the value of studies that have negative results. Document Drawer FDA Commissioner Marty Makary met with Sen. Steve Daines (R-Mont.) on July 30 to discuss abortion pill mifepristone, according to newly posted public calendar disclosures. He also held an introductory meeting with Sen. Amy Klobuchar (D-Minn.) on July 31. The FDA will hold a public meeting on Sept. 19 to discuss how to advance the development of interchangeable biosimilar products. The Health Resources and Services Administration is asking for feedback on its recommendation to add Duchenne muscular dystrophy and metachromatic leukodystrophy to the Recommended Uniform Screening Panel — a step that would require most insurers to cover the screenings without cost-sharing. WHAT WE'RE READING Costco will not dispense abortion pill mifepristone at its pharmacies, Bloomberg's Jeff Green and Jessica Nix report. President Donald Trump signed an executive order Wednesday directing HHS to stock drug ingredients to help bolster domestic supply, Lauren reports.
USA Today
an hour ago
- USA Today
Costco says it's not selling the abortion pill mifepristone
Costco will not be adding the abortion pill mifepristone to its pharmacies. Confirming the news to Reuters on Thursday, Aug. 14, Costco said the company will not sell the pill due to low demand. USA TODAY has contacted Costco for more information on the decision, but the company told Reuters that, typically, patients get the drug from their doctors. Mifepristone is a drug that blocks a hormone needed to continue pregnancy, according to the U.S. Food and Drug Administration (FDA). According to the FDA, mifepristone is taken with another drug called misoprostol to terminate pregnancies up to 10 weeks from the first day of the last menstrual period. The medications are taken over the course of two days. Mifepristone first got FDA approval in September 2000 for medical termination of pregnancy through seven weeks gestation; this was extended to 10 weeks in 2016. The FDA approved a generic version of the drug in 2019, according to the agency's website. Costco's announcement comes at a time when religious activist groups are pushing back against abortion drugs. Arguments against abortion drug, lawsuit explained In November 2022, a group of anti-abortion medical professionals sued the FDA in Texas federal district court, challenging its approval of the drug as well as expanded access to it. In April 2023, the U.S. Supreme Court sided with the group and suspended the FDA's approval of mifepristone. The court later issued an order that allowed individuals to have access to mifepristone during the appeals process. The Supreme Court then ruled in June 2024 that the religious group's case was to be dismissed because the group did not have 'the necessary legal standing to bring this challenge in federal court in the first place,' according to the Johns Hopkins Bloomberg School of Public Health. According to legal experts such as Joanne Rosen, a practice professor in Health Policy and Management at Johns Hopkins, plaintiffs must prove they have been hurt by the practices they're arguing against and that the government or agency was at fault. 'The coalition of plaintiffs were anti-abortion physicians and an anti-abortion medical association,' Rosen previously said about the case. 'None of them prescribe mifepristone or perform abortions. None of them have been required by FDA action to do so.' According to Johns Hopkins, another group or plaintiff could file a lawsuit of their own with more concrete evidence. Retailers targeted as part of anti-abortion campaigns While some stores, such as Walgreens and CVS, have chosen to sell mifepristone, other retailers haven't clarified whether they'll sell it. USA TODAY has reached out to three of those retailers — Walmart, Albertson's, and McKesson — for comment. Walmart declined to comment. Albertson's and McKesson did not immediately respond. "Many retailers have become more cautious about taking overt political or social stances after recent controversies triggered boycotts, negative media coverage, and polarized consumer reactions," Arun Sundaram, senior analyst at the California Family Rights Act, told Reuters. Religious groups such as Inspire Investing have credited themselves with keeping pharmacies from selling the drug. In December 2024, Kroger and Sam's Club allegedly began selling mifepristone in their pharmacies then said the pills were listed on their pharmacy websites by mistake, according to the Wisconsin Family Council. The council called out CVS and Walgreens for still offering abortion pills at their pharmacies. The drug has been the focal point of multiple protests as pro-choice groups demand continued access to the drug. Have there been deaths linked to mifepristone? According to the FDA, there have been 36 reports of deaths in patients associated with the medication since September 2000. This includes two ectopic pregnancies, which is when the fetus grows outside the womb, and multiple cases of sepsis. 'The adverse events cannot with certainty be causally attributed to mifepristone because of concurrent use of other drugs, other medical or surgical treatments, co-existing medical conditions, and information gaps about patient health status and clinical management of the patient,' the FDA said on its website. Contributing: Reuters Saleen Martin is a reporter on USA TODAY's NOW team. She is from Norfolk, Virginia – the 757. Email her at sdmartin@
